Everyone's IPF journey is unique, columnist Sam Kirton says, but that does not mean our experiences should become a competition.
United Therapeutics (UTHR) announced full enrollment of the TETON 1 study evaluating the use of Tyvaso or treprostinil, inhalation solution or ...
An imbalance in gene activity in two types of immune cells explains why lung fibrosis after a severe COVID-19 infection doesn ...
Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, and often fatal lung disease characterized by the scarring (fibrosis) of lung tissue, ...
Pulmonary fibrosis is a rare, chronic disease that causes scarring in the lungs, making breathing difficult for people who suffer with it.
Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that on January 21, 2025, it granted stock options to purchase an aggregate of 275,000 shares of common stock upon vesting to Delphine Imbert, ...
Garadacimab is under clinical development by CSL and currently in Phase II for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase II drugs for Idiopathic Pulmonary Fibrosis have a 35% phase ...
Walker had worked in radio for 58 years and had been previously diagnosed with idiopathic pulmonary fibrosis (IPF) – a chronic disease that causes irreversible scarring in the lungs.
Pulmonary rehabilitation (PR) may improve survival in patients with interstitial lung diseases including idiopathic pulmonary fibrosis (IPF) after 5 years but not after 10 years, according to a study ...
Management said the new name, logo, website and branding elements ... The biotech’s lead drug candidate is a potential treatment for idiopathic pulmonary fibrosis (IPF) that it picked up through ...
Walmart steel cage match (although we would totally watch). Instead, Walmart gave its logo a makeover fit for modern times—at least that was the idea. But people, well, they have feelings.
Walmart announced on Monday that it had unveiled a new logo, part of "a comprehensive brand refresh." The U.S.-based retailer boasted in a news release that the new look — its first change ...